scholarly article | Q13442814 |
P356 | DOI | 10.1056/NEJMRA1102942 |
P698 | PubMed publication ID | 22047562 |
P50 | author | Silvio Danese | Q89573798 |
P2093 | author name string | Claudio Fiocchi | |
P433 | issue | 18 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | colitis | Q2453464 |
P304 | page(s) | 1713-1725 | |
P577 | publication date | 2011-11-03 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | Ulcerative Colitis | |
P478 | volume | 365 |
Q89511747 | 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis |
Q35022882 | A 3D Polymer Model for Future Nutrition Design Novel Nutrition Approach for Cystic Fibrosis, Ulcerative Colitis and Crohn's Disease |
Q60047624 | A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation |
Q54933580 | A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease. |
Q36283368 | A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis |
Q42365590 | A Novel Role of Spred2 in the Colonic Epithelial Cell Homeostasis and Inflammation. |
Q38605223 | A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients with Ulcerative Colitis-associated Colorectal Cancer. |
Q92446581 | A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis |
Q53362870 | A Role for MYC in Lithium-Stimulated Repair of the Colonic Epithelium After DSS-Induced Damage in Mice. |
Q35973766 | A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease |
Q64997138 | A diet including xanthan gum triggers a pro-inflammatory response in Wistar rats inoculated with Walker 256 cells. |
Q36179468 | A gastroenterologist's guide to probiotics |
Q35238316 | A probabilistic model to predict clinical phenotypic traits from genome sequencing |
Q92525985 | A product review of vedolizumab in inflammatory bowel disease |
Q47387828 | A refined and translationally relevant model of chronic DSS colitis in BALB/c mice |
Q39023867 | A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010. |
Q35169255 | A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research |
Q38812824 | A systematic review of the role of DNA methylation on inflammatory genes in ulcerative colitis |
Q64106175 | ADP-ribosylation signalling and human disease |
Q27028024 | Achieving the best bowel preparation for colonoscopy |
Q47102876 | Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases |
Q36890647 | Acute blockade of IL-25 in a colitis associated colon cancer model leads to increased tumor burden |
Q38098468 | Adalimumab: a review of its use in the treatment of patients with ulcerative colitis |
Q34101549 | Alterations in the gut microbiome of children with severe ulcerative colitis |
Q35767401 | Altered Fecal Microbiota in Paediatric Inflammatory Bowel Disease |
Q58719404 | Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Rats by Keap1/Nrf-2 Activation, Intestinal Barrier Function, and Gut Microbiota Regulation |
Q51544073 | Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. |
Q28079322 | An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis |
Q64956401 | Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. |
Q37110983 | Andrographolide derivative AL-1 ameliorates TNBS-induced colitis in mice: involvement of NF-кB and PPAR-γ signaling pathways |
Q38816194 | Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. |
Q24187593 | Anti-MAdCAM antibody for induction of remission in ulcerative colitis |
Q38731835 | Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells |
Q46236112 | Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis |
Q90390539 | Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis |
Q89572940 | Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients |
Q37176942 | Association between Helicobacter Pylori infection and ulcerative colitis--a case control study from China |
Q34346345 | Association of the interleukin-22 genetic polymorphisms with ulcerative colitis |
Q90735821 | Associations between an MDM2 gene polymorphism and ulcerative colitis by ARMS-PCR |
Q37086842 | Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis |
Q92238029 | Berberine Protects Mice Against Dextran Sulfate Sodium-Induced Colitis by Activating mTORC1 Pathway |
Q51035866 | Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease. |
Q38262662 | Biological therapy for ulcerative colitis |
Q40078937 | Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting. |
Q38978344 | Biosimilars in IBD: from theory to practice |
Q38210630 | Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target |
Q35826470 | Bone marrow-derived mesenchymal stem cell transplantation ameliorates oxidative stress and restores intestinal mucosal permeability in chemically induced colitis in mice |
Q34474024 | Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis |
Q35905213 | CD101 inhibits the expansion of colitogenic T cells. |
Q56889158 | CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production |
Q55504526 | Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoids. |
Q42589189 | Carbohydrate Elimination or Adaptation Diet for Symptoms of Intestinal Discomfort in IBD: Rationales for "Gibsons' Conundrum". |
Q50966061 | Chemically induced mouse models of acute and chronic intestinal inflammation. |
Q41194978 | Chlorogenic Acid Ameliorates Experimental Colitis by Promoting Growth of Akkermansia in Mice |
Q35655815 | Chromosome-associated protein D3 promotes bacterial clearance in human intestinal epithelial cells by repressing expression of amino acid transporters |
Q53122367 | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. |
Q37387994 | Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis |
Q55424510 | Clinical Implication of Enlarged Prostate in Patients with the Ileal Pouch-anal Anastomosis for Inflammatory Bowel Disease. |
Q33865208 | Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles |
Q90656651 | Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis |
Q57065900 | Colonoscopic-guided pinch biopsies in mice: A useful model for evaluating the roles of host and luminal factors in colonic inflammation |
Q91764358 | Combined Signature of the Fecal Microbiome and Plasma Metabolome in Patients with Ulcerative Colitis |
Q97905242 | Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients |
Q47745759 | Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. |
Q53692282 | Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis. |
Q45083617 | Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. |
Q36530664 | Complete resolution of non-necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection. |
Q58764428 | Comprehensive analysis identifying aberrant DNA methylation in rectal mucosa from ulcerative colitis patients with neoplasia |
Q64055217 | Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review |
Q41912959 | Correlation of CCL20 expression in rectal mucosa with the development of ulcerative colitis-associated neoplasia |
Q90270023 | Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan |
Q39078228 | Crosstalk between intestinal epithelial cell and adaptive immune cell in intestinal mucosal immunity. |
Q38671272 | Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease |
Q38763559 | Current and emerging therapeutic targets for IBD. |
Q40500478 | Cutaneous manifestations in inflammatory bowel disease: a single institutional study of non-neoplastic biopsies over 13 years |
Q39206254 | Cytokines in inflammatory bowel disease |
Q28080901 | Cytokines, IBD, and colitis-associated cancer |
Q38850512 | Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. |
Q28083490 | Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review) |
Q42223966 | Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity? |
Q64097623 | Denitrase activity of reduces the oxidized compound 3-nitrotyrosine in mice liver with colitis |
Q28066449 | Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis |
Q35209892 | Diet, microbiota, and inflammatory bowel disease: lessons from Japanese foods. |
Q64091062 | Dietary Protein Intake Level Modulates Mucosal Healing and Mucosa-Adherent Microbiota in Mouse Model of Colitis |
Q91723286 | Dietary destabilisation of the balance between the microbiota and the colonic mucus barrier |
Q39167818 | Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. |
Q42293551 | Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study |
Q34075201 | Distinct kinetics in the frequency of peripheral CD4+ T cells in patients with ulcerative colitis experiencing a flare during treatment with mesalazine or with a herbal preparation of myrrh, chamomile, and coffee charcoal |
Q47583468 | Do patients living with ulcerative colitis adhere to healthy eating guidelines? A cross-sectional study |
Q28075218 | Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease |
Q37194925 | ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells |
Q47857757 | Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. |
Q41826640 | Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis |
Q49500932 | Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis |
Q37633139 | Effects of Herb-Partitioned Moxibustion on the miRNA Expression Profiles in Colon from Rats with DSS-Induced Ulcerative Colitis |
Q42097592 | Effects of Rhizophora mangle on Experimental Colitis Induced by TNBS in Rats |
Q28553419 | Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis |
Q28084236 | Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis |
Q64227685 | Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials |
Q49948526 | Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis |
Q48329328 | Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis |
Q36637710 | Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience |
Q54335763 | Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis. |
Q42375646 | Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges |
Q39306383 | Emerging treatments for ulcerative colitis: a systematic review. |
Q54273411 | Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha expression in colonic mucosa of patients with ulcerative colitis. |
Q26799615 | Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections |
Q39367550 | Epidemiological and clinical aspects of ulcerative colitis in west of Iran: a cross sectional study |
Q37578610 | Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt |
Q37992592 | Epigenetics: Concepts and relevance to IBD pathogenesis |
Q26853555 | Epigenetics: the fine-tuner in inflammatory bowel disease? |
Q27321681 | Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis |
Q35169275 | Etiopathogenesis of chronic inflammatory bowel diseases. Role of the immune system |
Q24186788 | Etrolizumab for induction of remission in ulcerative colitis |
Q24187269 | Etrolizumab for induction of remission in ulcerative colitis |
Q26801531 | Evaluating the Oxidative Stress in Inflammation: Role of Melatonin |
Q50613311 | Evaluation of cardiac function by two-dimensional speckle tracking echocardiography in ulcerative colitis patients. |
Q42872380 | Evidence against a systemic arterial defect in patients with inflammatory bowel disease |
Q37192429 | Expression Profile of p53 and p21 in Large Bowel Mucosa as Biomarkers of Inflammatory-Related Carcinogenesis in Ulcerative Colitis |
Q34437894 | Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis |
Q39852944 | Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan |
Q57184720 | Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1 |
Q36050474 | Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis |
Q40236724 | Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis |
Q33726429 | Fibroblast Growth Factor 21 Deficiency Attenuates Experimental Colitis-Induced Adipose Tissue Lipolysis |
Q26747341 | Fibroblasts, an inconspicuous but essential player in colon cancer development and progression |
Q42630337 | Forced treadmill exercise training exacerbates inflammation and causes mortality while voluntary wheel training is protective in a mouse model of colitis |
Q30844786 | Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. |
Q36006136 | Frequency and risk factors of primary sclerosing cholangitis among patients with inflammatory bowel disease in North-East of Iran |
Q38619050 | From Genes to Mechanisms: The Expanding Spectrum of Monogenic Disorders Associated with Inflammatory Bowel Disease |
Q52547514 | GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis. |
Q52353649 | Galectins in Intestinal Inflammation: Galectin-1 Expression Delineates Response to Treatment in Celiac Disease Patients. |
Q33781693 | Gene-gene and gene-environment interactions in ulcerative colitis. |
Q37217063 | Genetic mapping with multiple levels of phenotypic information reveals determinants of lymphocyte glucocorticoid sensitivity |
Q38794312 | Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. |
Q26866110 | Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications |
Q28236322 | Golimumab for the treatment of ulcerative colitis |
Q38218081 | Golimumab in unresponsive ulcerative colitis |
Q35990398 | Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I. |
Q38756562 | Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications |
Q27021781 | Gut-central nervous system axis is a target for nutritional therapies |
Q38836219 | Health utility of patients with Crohn's disease and ulcerative colitis: a systematic review and meta-analysis |
Q33867430 | Helminths in the gastrointestinal tract as modulators of immunity and pathology. |
Q38574126 | Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes |
Q92860876 | Hippocampal neural stem cells and microglia response to experimental inflammatory bowel disease (IBD) |
Q38896538 | How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease. |
Q47266007 | Human filarial proteins attenuate chronic colitis in an experimental mouse model. |
Q38082620 | Hydroxylases as therapeutic targets in inflammatory bowel disease. |
Q92786954 | IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease |
Q43783161 | IL-9 and its receptor are predominantly involved in the pathogenesis of UC. |
Q58108127 | IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling |
Q34568290 | IRGM variants and susceptibility to inflammatory bowel disease in the German population |
Q40480972 | Identification of a human intestinal myeloid cell subset that regulates gut homeostasis. |
Q50042967 | Immunological pathogenesis of inflammatory bowel disease |
Q38060831 | Immunosuppressive and biologic therapy for ulcerative colitis. |
Q38623451 | Impact of esophagogastroduodenoscopy and ileocolonoscopy on diagnosis and therapy in patients with rheumatic diseases-a retrospective cohort study |
Q33768802 | Impact of serum-derived bovine immunoglobulin/protein isolate therapy on irritable bowel syndrome and inflammatory bowel disease: a survey of patient perspective |
Q90656470 | Impact of therapies on bowel damage in Crohn's disease |
Q48259906 | Impaired resolution of DSS-induced colitis in mice lacking the glucocorticoid receptor in myeloid cells. |
Q35178414 | Impaired self-renewal and increased colitis and dysplastic lesions in colonic mucosa of AKR1B8-deficient mice |
Q55512056 | Improving IBD Care: A Personalized Approach to Management. |
Q46383363 | Increased Proliferation of the Pancreatic Duct Gland Compartment in Type 1 Diabetes |
Q59813626 | Increased Risk of Ulcerative Colitis in Patients with Periodontal Disease: A Nationwide Population-Based Cohort Study |
Q38830085 | Indole compounds may be promising medicines for ulcerative colitis. |
Q53146956 | Induced genome maintenance pathways in pre-cancer tissues describe an anti-cancer barrier in tumor development. |
Q93603852 | Inflammatory bowel disease |
Q35012080 | Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil |
Q39010059 | Inflammatory bowel disease: Traditional knowledge holds the seeds for the future |
Q27690759 | Inflammatory bowel disease: an increased risk factor for neurologic complications |
Q45269185 | Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate |
Q27005445 | Inflammatory pathways of importance for management of inflammatory bowel disease |
Q26765847 | Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases |
Q34784772 | Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis |
Q26764757 | Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer |
Q36715515 | Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity |
Q41024376 | Intestinal anti-inflammatory activity of Ground Cherry (Physalis angulata L.) standardized CO2 phytopharmaceutical preparation. |
Q40420311 | Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms. |
Q38217832 | Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? |
Q26865446 | Janus kinase inhibitors in autoimmune diseases |
Q28539860 | Job strain and the risk of inflammatory bowel diseases: individual-participant meta-analysis of 95,000 men and women |
Q40067106 | Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach. |
Q38125275 | Keeping the bowel regular: the emerging role of Treg as a therapeutic target in inflammatory bowel disease. |
Q37402440 | L13a-dependent translational control in macrophages limits the pathogenesis of colitis |
Q31143812 | Lineage-specific expression of bestrophin-2 and bestrophin-4 in human intestinal epithelial cells |
Q47673905 | Loss of acid ceramidase in myeloid cells suppresses intestinal neutrophil recruitment. |
Q90092673 | Lovastatin derivative dehydrolovastatin ameliorates ulcerative colitis in mice by suppressing NF-κB and inflammatory cytokine expression |
Q40966135 | Low-frequency ultrasound for drug delivery in the gastrointestinal tract |
Q38840924 | MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. |
Q38635974 | Management of inflammatory bowel disease with Clostridium difficile infection |
Q36212191 | Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin |
Q33819473 | Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease |
Q92097217 | Materials modulate immunity and gut microbiome |
Q57788239 | Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease |
Q47205215 | Media Consumption and Creation in Attitudes Toward and Knowledge of Inflammatory Bowel Disease: Web-Based Survey. |
Q38212225 | Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates |
Q34567518 | Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database |
Q37677012 | Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage |
Q48140849 | Mesenchymal stromal cells modulate gut inflammation in experimental colitis |
Q44607322 | Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery |
Q34821676 | MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. |
Q92714817 | MicroRNA-142-5p facilitates the pathogenesis of ulcerative colitis by regulating SOCS1 |
Q37702348 | MicroRNA-206 is involved in the pathogenesis of ulcerative colitis via regulation of adenosine A3 receptor |
Q36096047 | MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice |
Q27025092 | MicroRNAs in inflammatory bowel disease--pathogenesis, diagnostics and therapeutics |
Q35112183 | Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist |
Q47215602 | Microbiota dysbiosis in inflammatory bowel diseases: in silico investigation of the oxygen hypothesis |
Q26781311 | Mitochondrial dysfunction in inflammatory bowel disease |
Q34385980 | Mucus and the goblet cell |
Q26863622 | Murine models of inflammatory bowel disease (IBD): challenges of modeling human disease |
Q27314871 | MyD88 mediates the protective effects of probiotics against the arteriolar thrombosis and leukocyte recruitment associated with experimental colitis |
Q53075963 | Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects. |
Q92898593 | Network Pharmacology-Based Investigation into the Mechanisms of Quyushengxin Formula for the Treatment of Ulcerative Colitis |
Q38625992 | New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? |
Q64081049 | New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance |
Q35069777 | New strategies for treatment of inflammatory bowel disease |
Q38293802 | New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease |
Q35003977 | New targets for mucosal healing and therapy in inflammatory bowel diseases |
Q40013081 | Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring |
Q33625837 | Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation. |
Q54200104 | No association between the SOCS-1 -1478CA/del polymorphism and ulcerative colitis in Turkish subjects. |
Q38304488 | Noninvasive evaluation of active pan-ulcerative colitis with multiple strictures using Fluorine-18-Fluorodeoxyglucose positron emission tomography/computed tomography |
Q34486064 | Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. |
Q38161988 | Novel extended release budesonide formulation for treatment of ulcerative colitis |
Q41949151 | Novel treatment options for ulcerative colitis |
Q38831798 | Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients |
Q37600339 | Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study |
Q38727510 | Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis |
Q36753873 | Organizing pneumonia presenting after ulcerative colitis remission. |
Q42873201 | Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis |
Q28073745 | Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer |
Q39375417 | PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue |
Q42038488 | PPARγ in Inflammatory Bowel Disease |
Q37626292 | Palisaded Granulomatous Dermatitis Associated with Ulcerative Colitis: A Comprehensive Literature Review |
Q48182579 | Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab. |
Q38357630 | Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis |
Q38665573 | Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders |
Q26796432 | Patient considerations in the management of ulcerative colitis - role of vedolizumab |
Q28069324 | Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions? |
Q64262376 | Personalising medicine in inflammatory bowel disease-current and future perspectives |
Q93159935 | Phospholipid-Based Prodrugs for Colon-Targeted Drug Delivery: Experimental Study and In-Silico Simulations |
Q33810986 | Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis |
Q50609014 | Piroxicam treatment augments bone abnormalities in interleukin-10 knockout mice. |
Q36081139 | Pleomorphic malignant histiocytoma: a rare skin cancer in a patient on azathioprine for ulcerative colitis |
Q50426415 | Positive correlation between disease activity index and matrix metalloproteinases activity in a rat model of colitis. |
Q40382305 | Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients |
Q41358364 | Primary rectal diffuse large B-cell lymphoma associated with ulcerative colitis: a case report |
Q40447506 | Probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice. |
Q90116607 | Profiling the lncRNA-miRNA-mRNA ceRNA network to reveal potential crosstalk between inflammatory bowel disease and colorectal cancer |
Q45862997 | Proinflammatory progranulin antibodies in inflammatory bowel diseases |
Q38588839 | Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature |
Q50470840 | Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. |
Q36964100 | Protective effects of ethanol extract from Portulaca oleracea L on dextran sulphate sodium-induced mice ulcerative colitis involving anti-inflammatory and antioxidant |
Q34339382 | Proteomic analysis of colonic mucosal tissue from tuberculous and ulcerative colitis patients |
Q60302490 | Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review |
Q37054120 | Qingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response |
Q58787826 | Radiological Patterns of Lung Involvement in Inflammatory Bowel Disease |
Q90325399 | Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States |
Q39132618 | Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease |
Q35012024 | Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation |
Q58544445 | Rectal Lymphoid Follicle Aphthous Lesions Frequently Progress to Ulcerative Colitis with Proximal Extension |
Q48119825 | Regulating the Balance of Th17/Treg via Electroacupuncture and Moxibustion: An Ulcerative Colitis Mice Model Based Study. |
Q39662763 | Regulation of Laminin γ2 Expression by CDX2 in Colonic Epithelial Cells Is Impaired During Active Inflammation |
Q37986197 | Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers |
Q47134262 | Relation between NOD2 genotype and changes in innate signaling in Crohn's disease on mRNA and miRNA levels |
Q34575468 | Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and Transcriptomic [corrected] characterization and correlation to IBD. |
Q34813567 | Relevance of commensal microbiota in the treatment and prevention of inflammatory bowel disease |
Q96348665 | Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial |
Q34463139 | Republished: tracing PAKs from GI inflammation to cancer |
Q26747410 | Resolution of Inflammation: What Controls Its Onset? |
Q51191479 | Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis. |
Q42160189 | Results from a retrospective analysis of colonoscopies for Inflammatory bowel disease and colorectal cancer in a Lebanese tertiary care centre |
Q38828436 | Review article: the pathogenesis of pouchitis |
Q40069311 | Risk factors and clinical implication of superimposed Campylobacter jejuni infection in patients with underlying ulcerative colitis |
Q87691389 | Risk of cardiovascular disease in inflammatory bowel disease |
Q50473979 | Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. |
Q90079459 | Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study |
Q60920231 | Role of endoscopy in the surveillance and management of colorectal neoplasia in inflammatory bowel disease |
Q26768560 | Role of regulatory T cell in the pathogenesis of inflammatory bowel disease |
Q90341495 | Roles of Ceramides and Other Sphingolipids in Immune Cell Function and Inflammation |
Q54758338 | Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? |
Q55128199 | Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis. |
Q38867779 | Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis |
Q38947390 | Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. |
Q37114622 | Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results |
Q98612722 | Secondary causes of inflammatory bowel diseases |
Q38086247 | Serological markers of inflammatory bowel disease |
Q36030169 | Serum Fatty Acids Are Correlated with Inflammatory Cytokines in Ulcerative Colitis |
Q49682864 | Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis |
Q90170171 | Sesamin Enhances Nrf2-Mediated Protective Defense against Oxidative Stress and Inflammation in Colitis via AKT and ERK Activation |
Q41876201 | Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease |
Q38653299 | Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy |
Q39041028 | Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study |
Q36062250 | Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis |
Q37522688 | Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. |
Q35121243 | Shuttling of information between the mucosal and luminal environment drives intestinal homeostasis |
Q47209789 | Simultaneous inference of phenotype-associated genes and relevant tissues from GWAS data via Bayesian integration of multiple tissue-specific gene networks. |
Q44390503 | Skin Manifestations of Inflammatory Bowel Disease |
Q39014759 | Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis |
Q92279683 | Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases |
Q42361175 | Steroid-sparing strategies in the management of ulcerative colitis: efficacy of leukocytapheresis. |
Q92635301 | Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis |
Q38214577 | Surgical Management of Severe Colitis in the Intensive Care Unit |
Q38575522 | Surgical and medical treatment in patients with acute severe ulcerative colitis |
Q64264125 | Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease |
Q38222449 | Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis |
Q38837599 | Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. |
Q47368151 | Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis |
Q92156124 | Systems Pharmacology and Microbiome Dissection of Shen Ling Bai Zhu San Reveal Multiscale Treatment Strategy for IBD |
Q46547713 | TGF-β Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota. |
Q56671802 | TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells |
Q42404774 | TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration |
Q37322789 | TNF-α Autocrine Feedback Loops in Human Monocytes: The Pro- and Anti-Inflammatory Roles of the TNF-α Receptors Support the Concept of Selective TNFR1 Blockade In Vivo. |
Q34508085 | TNF-α blockade is ineffective in animal models of established polycystic kidney disease |
Q89866491 | TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity |
Q37015317 | Takayasu arteritis associated with ulcerative colitis and optic neuritis: first case in Korea |
Q38172801 | Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy? |
Q40882156 | Technetium-99 m labeling and evaluation of olsalazine: a novel agent for ulcerative colitis imaging |
Q35043258 | Temporal comorbidity of mental disorder and ulcerative colitis |
Q39006003 | Th9 cells in inflammatory bowel diseases |
Q46443053 | The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis |
Q64880511 | The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis. |
Q41278499 | The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial |
Q93079402 | The Effect of Vitamin D on Serum Asymmetric Dimethylarginine in Patients with Mild to Moderate Ulcerative Colitis |
Q35897490 | The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds |
Q41473592 | The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis |
Q33790179 | The GTPase-activating protein GIT2 protects against colitis by negatively regulating Toll-like receptor signaling |
Q90234037 | The Gut-Liver Axis in Primary Sclerosing Cholangitis: Are Pathobionts the Missing Link? |
Q39077548 | The Immunological Basis of Inflammatory Bowel Disease |
Q87288268 | The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications |
Q47109861 | The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. |
Q35247723 | The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease |
Q38600839 | The Proteome of Ulcerative Colitis in Colon Biopsies from Adults - Optimized Sample Preparation and Comparison with Healthy Controls |
Q57115319 | The Relationship between Gender, Severity of Disease, Treatment Type, and Employment Outcome in Patients with Inflammatory Bowel Disease in Israel |
Q39444977 | The Risk of Inflammatory Bowel Disease Flares after Fecal Microbiota Transplantation: Systematic Review and Meta-Analysis. |
Q55304582 | The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. |
Q52448502 | The application of molecular topology for ulcerative colitis drug discovery. |
Q26745725 | The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes |
Q40154191 | The effect of algal polysaccharides laminarin and fucoidan on colonic pathology, cytokine gene expression and Enterobacteriaceae in a dextran sodium sulfate-challenged porcine model. |
Q59791119 | The emerging role of lncRNAs in inflammatory bowel disease |
Q37197292 | The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery |
Q35085141 | The impact of primary and persistent cytomegalovirus infection on the progression of acute colitis in a murine model |
Q38996677 | The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology. |
Q47884736 | The role of alpha7 nicotinic acetylcholine receptors in inflammatory bowel disease: involvement of different cellular pathways |
Q38820563 | The role of specialty pharmacy drugs in the management of inflammatory diseases |
Q54454921 | The safety and efficacy of adalimumab in patients with Crohn's disease: the experience of a single Canadian tertiary care centre. |
Q26862713 | The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis |
Q42427911 | The zinc sensing receptor, ZnR/GPR39, triggers metabotropic calcium signalling in colonocytes and regulates occludin recovery in experimental colitis. |
Q38950433 | The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo |
Q36522931 | Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? |
Q38820319 | Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients |
Q47822938 | Tissue IgG4-positive plasma cells in inflammatory bowel disease: a study of 88 treatment-naive biopsies of inflammatory bowel disease. |
Q36759434 | Tissue-resident dendritic cells and diseases involving dendritic cell malfunction |
Q44603472 | ToF-SIMS and principal component analysis of lipids and amino acids from inflamed and dysplastic human colonic mucosa |
Q92628027 | Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation |
Q38401205 | Tracheal and bronchial involvement in colitis ulcerosa - a colo-bronchitic syndrome? A case report and some additional considerations |
Q38210506 | Tracing PAKs from GI inflammation to cancer. |
Q44696806 | Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study |
Q37463907 | Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis |
Q39172441 | Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK |
Q64254092 | Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases |
Q40140168 | Two Cases of Severe Ulcerative Colitis with Colonic Dilatation Resolved with Tacrolimus Therapy |
Q40074887 | Type 2 immunity in tissue repair and fibrosis |
Q39278916 | Ulcerative Colitis Symptomatology and Depression: The Exacerbator Role of Maladaptive Psychological Processes |
Q35781294 | Ulcerative Colitis: Update on Medical Management |
Q35957812 | Ulcerative colitis presenting as acute infectious gastroenteritis with a paralytic ileus |
Q33573189 | Ulcerative colitis six years after colon cancer: only a coincidence? |
Q51032601 | Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. |
Q51044431 | Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice. |
Q27325548 | Ultrasound-mediated gastrointestinal drug delivery |
Q34030650 | Update on Janus kinase antagonists in inflammatory bowel disease |
Q36144377 | Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine |
Q37236388 | Usefulness of sulfasalazine for patients with refractory-ulcerative colits |
Q90293727 | Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study |
Q41289466 | Utility of CT in the emergency department in patients with ulcerative colitis |
Q93108869 | Validation of US evaluation of ulcerative colitis activity |
Q42107239 | Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis |
Q34326912 | Vedolizumab for Crohn's disease |
Q38610119 | Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
Q33996708 | Xilei san ameliorates experimental colitis in rats by selectively degrading proinflammatory mediators and promoting mucosal repair. |
Q90542917 | siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease |
Q94076162 | siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease |
Search more.